For Richard “Rocky” Kimball, a diagnosis of myelodysplastic syndromes, or MDS, necessitated a number of lifestyle changes.
Hypomethylating agents are standard in MDS treatment, with new drugs like Rytelo enhancing anemia management. Targeted therapies for IDH1/IDH2 mutations offer promising options, though challenges in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results